LTR is comprised of medical, regulatory, and financial experts. Team members share several core attributes, including: a passion for what we do, attention to detail, resourcefulness, business intelligence, and integrity.
Joel B. Braunstein, MD, MBA
Founder, Chief Executive Officer
Dr. Braunstein co-founded LifeTech Research (LTR) in 2003. He is a board-certified cardiologist and internist. In addition to guiding the vision and strategy of LTR and various of its affiliate companies, he provides analytics in the areas of clinical trial design and methods, outcomes research, and healthcare policy and economics. Through LTR and its affiliates, Dr. Braunstein has played a key operational role in the start-up of numerous life sciences companies. He currently sits on five corporate boards: C2N Diagnostics, a rapidly emerging Alzheimer’s (and other neurodegenerative disorder) diagnostics and biomarker company; Centegen, Inc, a therapeutics company developing novel agents against drug-resistant staphylococci; NexGen Medical Systems and Correx, device companies each developing transformative minimally-invasive surgical and vascular interventional devices; and Tivorsan Pharmaceuticals, a biologics company developing a recombinant protein for a serious genetic disorder.
Ilana Fogelman, MD, MPH
Founder, Chief Operating Officer
Dr. Fogelman co-founded LifeTech Research in 2003. She specializes in corporate and product pipeline valuation, drug development, clinical trial design and analysis, and FDA regulations. Her primary responsibility at LTR is to oversee operations, in addition to identifying and evaluating investment opportunities in companies with emerging life sciences technologies. She also evaluates regulatory strategies and risk, and helps clients interpret FDA actions, decisions and requirements.
Micah Onixt, JD, MBA
Mr. Onixt brings approximately 15 years of life sciences work experience to LifeTech Research and its affiliate companies. Most recently, he was a partner in the Chicago office at DLA Piper LLP US and a recipient of the “40 Illinois Attorneys Under 40 to Watch” award from the Law Bulletin Publishing Company. During his twelve year tenure at DLA Piper, his practice consisted of representing both institutional investment funds, and private and public life sciences companies in the areas of corporate securities, technology transfer (product licensing, M&A), and intellectual property management. He has negotiated dozens of partnerships; and drafted and prosecuted patents, copyrights, and trade secrets within the biotechnology, pharmaceutical and medical device spaces.
Ellen Brady, MD, MPH
Vice-President, Clinical and Regulatory Research
Dr. Brady joined LTR in 2004. She is a board certified general internist with a master’s degree in public health from the Johns Hopkins School of Hygiene and Public Health. Her early career in academia focused on issues related to healthcare delivery, international health and public policy. Currently, an adjunct professorship within the University of Utah College of Pharmacy Pharmacotherapy Outcomes Research Center allows continued expression of those interests. Subsequently, and prior to LifeTech, Dr. Brady spent 20 years within the pharmaceutical industry, working for both major (Sandoz, Ciba-Geigy, Janssen Pharmaceuticals and Serono) and development-stage companies (NPS Pharmaceuticals and Esperion Therapeutics). Most recently, she was Senior Director, Clinical Research at Esperion prior to its acquisition by Pfizer.